BioPharm Systems announced that it has launched a new solution which enables life sciences companies that use Oracle Clinical, Oracle's clinical data management system, to copy studies between Oracle Clinical environments.
The Oracle Clinical Study Copy Tool is a flexible application that can be used for tasks such as transferring clinical studies from one Oracle Clinical instance to another, archiving a global library or clinical studies, and refreshing patient data in a non-production environment.
"We originally developed this Oracle Clinical application for a company that needed to migrate their global library and clinical studies from an external Oracle Clinical instance to a BioPharm Systems hosted environment," said Michelle Engler, principal consultant, BioPharm Systems. "During the development of the solution, several other companies showed interest in its broad capabilities, so we decided to release it to the greater clinical trials community."
Pharmaceutical, biotechnology, and medical device companies, in addition to clinical research organizations and academic institutions who license the solution can choose to either employ it on their own or have BioPharm Systems service their specific needs. Although it has zero footprint in Oracle Clinical, the application's security is maintained via Oracle Clinical and its standard credential controls.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.